Bhavana (Tina) Bhatnagar, DO

Bhavana Bhatnagar, DO, who moved from academic to community oncology, shares why stronger academic-community partnerships are essential for patient care

Bhavana “Tina” Bhatnagar, DO, reflects on AML’s transformation from few treatment options to targeted therapies and efforts to increase access to them.

Bhavana (Tina) Bhatnagar, DO, explains how age, comorbidities, fertility, and individual goals drive personalized treatment decisions in ALL and AML.

A comprehensive approach is necessary for navigating the highly heterogeneous nature of leukemia across different age populations, explains Tina Bhatnagar, DO.

Bhavana (Tina) Bhatnagar, DO, advocates for AI and diverse clinical trials to bridge equity gaps in precision oncology and value-based care.

Tina Bhatnagar, DO, speaks to the importance of diversity in clinical trials and the need to remove barriers, enroll underrepresented backgrounds, and reflect real-world health conditions.

Bhavana (Tina) Bhatnagar, DO, discusses the transformative role of AI in enhancing patient care at West Virginia University Cancer Institute.

Despite the impact of targeted treatment in oncology, much work remains to bring these therapeutics to all patients, says Bhavana (Tina) Bhatnagar, DO.